VRTX · 10-Q · 2026Q2 · Full report
Income Tax Rate Changes
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 44 · Surprise 58 · In source text
Vertex’s effective tax rate was 16.6% in the first half of 2026, down from 19.4% in the first half of 2025, a decline of 2.8 percentage points. The lower 2026 rate was primarily attributable to excess tax benefits from stock-based compensation and tax credits. H.R.1, enacted in July 2025, permits immediate deduction of 2025 R&D expenditures and deductions for previously capitalized amounts. H.R.1 had no material impact on U.S. taxes in the first half of 2026, but future guidance could affect future effective tax rates, tax liabilities, and cash taxes.
Key facts
- U.S. enacted H.R.1 in July 2025 including provisions to immediately deduct R&D expenditures for 2025; H.R.1 does not have a material impact on U.S. taxes for first half of 2026 but may impact future effective tax rates source
- Our effective tax rate in the first half of 2026: 19.4%, lower than U.S. statutory rate primarily due to excess tax benefits related to stock-based compensation source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | probable | — | U.S. enacted H.R.1 in July 2025 including provisions to immediately deduct R&D expenditures for 2025; H.R.1 does not have a material… |